Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5701118 | European Journal of Surgical Oncology (EJSO) | 2016 | 7 Pages |
Abstract
TP did not offer any significant OS and CSS benefits as compared to PD. However, for patients in stage T4 and AJCC stage III, TP may extend survival time in some degree. In older or histologically poorly differentiated patients, PD may be preferable to TP. The results are rational, but still warrant further verification due to limited sample volumes of specific subgroups.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
X. Wang, X. Hong, H. Pang, H. Dai, L. You, W. Wu, Y. Zhao,